Display options
Cite
Wilson AJ, Barham W, Saskowski J, et al. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013;6(1):63doi: 10.1186/1757-2215-6-63.
Wilson, A. J., Barham, W., Saskowski, J., Tikhomirov, O., Chen, L., Lee, H. J., Yull, F., & Khabele, D. (2013). Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. Journal of ovarian research, 6(1), 63. https://doi.org/10.1186/1757-2215-6-63
Wilson, Andrew J, et al. "Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model." Journal of ovarian research vol. 6,1 (2013): 63. doi: https://doi.org/10.1186/1757-2215-6-63
Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res. 2013 Sep 10;6(1):63. doi: 10.1186/1757-2215-6-63. PMID: 24020521; PMCID: PMC3846584.
Copy Download .nbib Format: NLM
Share it on

J Ovarian Res. 2013 Sep 10;6(1):63. doi: 10.1186/1757-2215-6-63.

Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.

Journal of ovarian research

Andrew J Wilson, Whitney Barham, Jeanette Saskowski, Oleg Tikhomirov, Lianyi Chen, Hye-Jeong Lee, Fiona Yull, Dineo Khabele

Affiliations

  1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University Medical Center, B1100 Medical Center North, Nashville, TN 37232, USA. [email protected].

PMID: 24020521 PMCID: PMC3846584 DOI: 10.1186/1757-2215-6-63

Abstract

BACKGROUND: Nuclear factor-kappa B (NF-kappaB) signaling is an important link between inflammation and peritoneal carcinomatosis in human ovarian cancer. Our objective was to track NF-kappaB signaling during ovarian cancer progression in a syngeneic mouse model using tumor cells stably expressing an NF-kappaB reporter.

METHODS: ID8 mouse ovarian cancer cells stably expressing an NF-kappaB-dependent GFP/luciferase (NGL) fusion reporter transgene (ID8-NGL) were generated, and injected intra-peritoneally into C57BL/6 mice. NGL reporter activity in tumors was non-invasively monitored by bioluminescence imaging and measured in luciferase assays in harvested tumors. Ascites fluid or peritoneal lavages were analyzed for inflammatory cell and macrophage content, and for mRNA expression of M1 and M2 macrophage markers by quantitative real-time RT-PCR. 2-tailed Mann-Whitney tests were used for measuring differences between groups in in vivo experiments.

RESULTS: In ID8-NGL cells, responsiveness of the reporter to NF-kappaB activators and inhibitors was confirmed in vitro and in vivo. ID8-NGL tumors in C57BL/6 mice bore histopathological resemblance to human high-grade serous ovarian cancer and exhibited similar peritoneal disease spread. Tumor NF-kappaB activity, measured by the NGL reporter and by western blot of nuclear p65 expression, was markedly elevated at late stages of ovarian cancer progression. In ascites fluid, macrophages were the predominant inflammatory cell population. There were elevated levels of the M2-like pro-tumor macrophage marker, mannose-receptor, during tumor progression, and reduced levels following NF-kappaB inhibition with thymoquinone.

CONCLUSIONS: Our ID8-NGL reporter syngeneic model is suitable for investigating changes in tumor NF-kappaB activity during ovarian cancer progression, how NF-kappaB activity influences immune cells in the tumor microenvironment, and effects of NF-kappaB-targeted treatments in future studies.

References

  1. Nature. 2009 Nov 5;462(7269):104-7 - PubMed
  2. Mol Cancer Res. 2008 Jun;6(6):1059-70 - PubMed
  3. Nature. 2004 Sep 23;431(7007):405-6 - PubMed
  4. Carcinogenesis. 2000 Apr;21(4):585-91 - PubMed
  5. Trends Immunol. 2004 Jun;25(6):280-8 - PubMed
  6. Science. 2013 Jan 18;339(6117):286-91 - PubMed
  7. Mol Biol Cell. 2008 Oct;19(10):4062-75 - PubMed
  8. J Immunol. 2005 Jul 15;175(2):1197-205 - PubMed
  9. Cancer Cell. 2004 Sep;6(3):203-8 - PubMed
  10. Nat Rev Cancer. 2009 Jun;9(6):415-28 - PubMed
  11. J Pathol. 2000 Apr;190(5):537-44 - PubMed
  12. Cancer Res. 2005 Nov 15;65(22):10355-62 - PubMed
  13. Am J Reprod Immunol. 2012 Mar;67(3):256-65 - PubMed
  14. Adv Exp Med Biol. 2008;622:169-81 - PubMed
  15. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed
  16. Cell Res. 2008 Mar;18(3):334-42 - PubMed
  17. Cancer Immun. 2013;13:1 - PubMed
  18. Cancer Biol Ther. 2007 May;6(5):795-801 - PubMed
  19. Cancer Res. 2007 Jan 15;67(2):585-92 - PubMed
  20. Breast Cancer Res. 2011 Aug 31;13(4):R83 - PubMed
  21. J Immunol. 2011 Jun 15;186(12):6905-13 - PubMed
  22. J Immunol. 2006 Apr 15;176(8):5023-32 - PubMed
  23. Nature. 2002 Dec 19-26;420(6917):860-7 - PubMed
  24. Cancer Cell. 2005 Mar;7(3):211-7 - PubMed
  25. Cancer Res. 2010 May 15;70(10):4005-14 - PubMed
  26. Mol Cancer Res. 2008 Mar;6(3):364-71 - PubMed
  27. J Clin Oncol. 2008 Feb 20;26(6):995-1005 - PubMed
  28. Int J Clin Exp Pathol. 2012;5(1):37-45 - PubMed
  29. Methods. 2001 Dec;25(4):402-8 - PubMed
  30. Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L320-7 - PubMed
  31. Am J Surg Pathol. 2010 May;34(5):627-35 - PubMed
  32. J Immunol. 2006 Apr 15;176(8):4995-5005 - PubMed
  33. Biochem Biophys Res Commun. 2012 Jan 13;417(2):864-8 - PubMed
  34. Nature. 2004 Sep 23;431(7007):461-6 - PubMed
  35. Oncogene. 2006 Oct 30;25(51):6817-30 - PubMed
  36. J Exp Med. 2008 Jun 9;205(6):1261-8 - PubMed
  37. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  38. J Pathol. 2012 Jun;227(2):136-45 - PubMed
  39. Cancer Res. 2007 Jun 15;67(12):5708-16 - PubMed
  40. Cancer Biol Ther. 2007 Aug;6(8):1302-12 - PubMed

Publication Types

Grant support